Global 3D Bioprinting Market - 2023-2030

Global 3D Bioprinting Market - 2023-2030

Global 3D Bioprinting Market reached US$ 2.0 billion in 2022 and is expected to reach US$ 6.4 billion by 2030 growing with a CAGR of 16.1% during the forecast period 2023-2030.

In the additive manufacturing method known as 3D bioprinting, living cells and nutrients are joined with organic and biological components to produce synthetic structures that resemble natural human tissues. The branches of tissue engineering, bioengineering, and materials science can all benefit from 3D bioprinting for a variety of biological applications. Additionally, the technology is increasingly being used for drug research and approval. The present focus of bioprinting research is on clinical applications including 3D printed skin and bone grafts, implants, and even complete 3D printed organs.

Additionally, factors such as the rising adoption of government initiatives, and incentive programs, the rising use of 3D bioprinters in beauty treatments and advancements, the use of 3D bioprinting in clinical studies and drug screening which helps to reduce animal testing, are driving the growth of the 3D Bioprinting market size. Due to the massive rise in technological advancements in countries like the U.S. and Canada, the market is experincing an rise in demand from North American regions.

Market Dynamics

The Strategies Followed by the Companies Helps to Drive the Market Growth

The strategies like product launches, product approvals, partnerships and acquisitions helps to drive the market growth. For instance, in March 2021, the BIO MDX Series, the most recent generation of bioprinters created for high-throughput biofabrication and precise 3D bioprinting for biomedical production, including the creation of biocompatible medical equipment, has been introduced by CELLINK, the leading bioconvergence firm in the world.

There has been a larger need for better automation, precision, and repeatability across biofabrication techniques over the past five years as 3D bioprinting has grown in popularity as the technique of choice for researchers working in the fields of tissue engineering, cell culture, and regenerative medicine.

Additionally, on November 22, 2022, an Indian tech start-up called Avay Biosciences has unveiled a homegrown 3D printer that, according to the company, can manufacture human tissues. At the Indian Institute of Science, the 'Mito Plus' bioprinter's first prototype was installed. The sophisticated Bio 3D printer Mito Plus was created by Avay, which was co-founded by an IIT Madras alumnus, with feedback on the prototype from the research lab at IISc. Thus, an increase in new product launches contributes to market expansion.

Technological Advancements in the Treatment

The objective of 3D bioprinting has advanced significantly in recent years, and it is now possible to print organs that can be successfully transplanted into people. Even while that is still a long way off, the technique is still being researched and developed, and advancements could result in new and better therapies for ailments including brain cancer, Parkinson's disease, Alzheimer's disease, and spinal cord injury, among many others.

With a few modifications, normal 3D printing techniques are used to create living cells in 3D. In accordance with a CAD file, the printer applies material in successive layers to create a shape. Bioinks are the materials used by bioprinters instead of metals or polymers. These are made of viscous substances like alginate or gelatin and contain living cells. Scaffolding is frequently used to support and safeguard the cells while they are created. The 3D bioprinting business is expanding as a result of many recent advancements.

For instance, according to American Society of Mechnical Engineers, new invention is a portable 3D printer that deposits sheets of biomaterial skin to cover big burn wounds. Additionally, the biomaterial speeds up the healing process. The technology, developed by researchers at Sunnybrook Hospital and the University of Toronto in Toronto, applies bio ink to burn wounds strip by strip. The mesenchymal stroma cells (MSCs), stem cells that can develop into multiple cell types depending on their environment, are used to make the biomaterial. Thus, the growth of technology contributes to market expansion.

High cost of Treatment

Even though many people believe that using this advanced technology will allow patients to have an organ transplant as soon as possible, the operation is not affordable. The cost of having anything done increases as technology advances. The cost of the materials required for bioprinting organs has also increased.

While producing living tissues can cost as little as $1,000, the majority of bioprinters used for 3D organ printing can cost as much as $100,000. Organ printing is expensive due to the fact that it takes a lot of time to do the needed research and because it needs highly qualified and experienced workers to make sure the process is effective. Thus due to expensive cost of organs will restrict the market growth.

Segment Analysis

The global 3D bioprinting market is segmented based on component, technology, application, end user and region.

The Hospitals Accounted for Approximately 31.07% of the 3D Bioprinting Market Share

Using 3D bioprinting, surgeons may make patient-specific organ models. By enabling them to visualize the patient's particular anatomy and perform the procedure beforehand, these models can aid them in planning complicated surgeries. This may result in surgeries that are more successful and accurate. Surgeons can produce tissue constructions from a patient's own cells using 3D bioprinting. The use of these constructions as grafts or replacements can help in tissue regeneration. In order to help surgeons better prepare for operation, 3D printing also enables medical personnel to create reference models from MRI and CT scans, which is driving the segment's revenue growth.

Moreover, strategic collaborations between major market companies and hospitals for the implementation of 3D printing for healthcare purposes is driving revenue growth of this segment.For instance, in Feburary 2021, Anatomiz3D Medtech and the Apollo Hospitals have worked collaboratively to design and construct hospital 3D printing facilities in India that would allow surgeons to visualize and manufacture implants for challenging surgical cases. The medical and surgical staff at Apollo Hospitals will collaborate with a multidisciplinary team made up of engineers and 3D designers in the hospital's 3D printing facilities. Thus, those mentioned elements aid in accelerating segment expansion.

Geographical Penetration

North America Accounted for Approximately 44.9% of the Market Share in 2022

The 3D bioprinting market is expanding in this region due to the increasing use of 3D bioprinting in hospitals for its features. The outstanding medical education and training programs in North America produce a workforce that is ready for implementing innovative technologies, such 3D bioprinting, in hospitals and clinics. Moreover, rising investments from companies and governmental entities, in addition to technological advancements in healthcare infrastructure are some factors helps to accelerate region growth.

For instance, in June 2023, In order to improve 3D bioprinting, 3D BioFibR, a Canadian tissue engineering company, has launched two new collagen fiber products: CollaFibR and CollaFibR 3D scaffold. The innovative, exclusive dry-spinning process developed by 3D BioFibR, which can produce collagen fibers at industrial scales, is used to make these new off-the-shelf products. According to details, these new products will provide significant benefits for applications involving tissue engineering and tissue culture. Thus, all of the above factors contribute to the region's growth.

Competitive Landscape

The major global players in the 3D bioprinting market Organovo Holdings Inc, UPM Biomedicals, GE Healthcare, Regemat 3D, 3DSMAN, CELLINK, Aspect Biosystem, Formlabs, Avay Biosciences, Precise Bio and others.

COVID-19 Impact Analysis

A variety of chronic disorders have been caused by the worldwide pandemic, aiding in the unexpected expansion of the 3D bioprinting companies. Healthcare professionals, the community, and the government face new challenges with each COVID-19 wave in terms of minimizing its impact and aftereffects. The last multiple waves encountered a problem with the shortage of COVID-19 test kits.

This significant issue was addressed by numerous 3D bioprinting companies, and test kits were produced in huge quantities. According to reports, Formlabs, one of the American businesses, produced 100,000 nose swabs for COVID-19 testing per day. Recently, a great number of pharmaceutical firms, R&D centers, and healthcare professionals have united to battle this terrible global pandemic in every way available.

By Component
• 3D Bioprinters
• Bioinks

By Technology
• Extrusion-based bioprinting
• Inkjet-based bioprinting
• Pressure-assisted bioprinting
• Laser-assisted bioprinting
• Others

By Application
• Medical
Tissue And Organ Generation
Medical Pills
Prosthetics And Implants
Others
• Dental
• Biosensors
• Consumer/Personal Product Testing
• Others

By End User
• Hospitals
• Research Organizations and Academic Institutes
• Biopharmaceutical Companies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• In Feburary 2023, an new strategy for surgical operations requiring the reconstruction of human tissues has been developed by 3D Systems as a component of its tissue regeneration program. After making great strides in the creation of advanced bioprinting solutions for 3D printed solid organs, the company launched this program.
• In March 2023, LabSkin and Chanel produce 3D bioprinted skin with spots. In order to advance its understanding of skin pigment spots, a key cosmetic problem among aging populations, particularly in Asia,. The luxury brand has successfully employed 3D bioprinting technologies to generate reconstructed human skin on which a dark spot can form in collaboration with LabSkin Creations.
• In June 2022, the first multi-material, multi-fluidic bioprinting printhead, according to Finland-based bioprinting company Brinter, has been introduced. The digital multifluidic printing tool head is now undergoing pilot testing with a small number of customers. It was created for use with the company's own 3D bioprinters and geared toward pharmaceutical firms and research universities.

Why Purchase the Report?
• To visualize the global 3D bioprinting market segmentation based on component, technology, application, end user and region as well as understandkey commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of 3D bioprinting market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global 3D bioprinting market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies